|
128 Companies |
|
121 Products |
|
121 Products |
|
104 Mechanisms of Action |
|
7 Trials |
|
1812 News |
|
| «12...2526272829303132333435...3637» |
- || Enrollment change: EIBS in BE: Early Increase in Blood Supply in Patients With Barrett's Esophagus (clinicaltrials.gov) - Apr 25, 2013
P=N/A, N=90, Completed, Sponsor: Mayo Clinic
N=30 --> 90
- ||| Trial completion: EIBS in BE: Early Increase in Blood Supply in Patients With Barrett's Esophagus (clinicaltrials.gov) - Apr 25, 2013
P=N/A, N=90, Completed, Sponsor: Mayo Clinic
N=30 --> 90 Recruiting --> Completed
- Gastrocrom (cromolyn) / Viatris
New P1 trial: Cromolyn Detection of Silent Aspiration (clinicaltrials.gov) - Apr 24, 2013
P1, N=15, Not yet recruiting, Sponsor: University of California, San Francisco
- oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy, Surgery: Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer (clinicaltrials.gov) - Apr 22, 2013
P2, N=41, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=1, Completed, Sponsor: University of California, Davis
Active, not recruiting --> Completed N=50 --> 1
- ||| Enrollment closed: Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD) (clinicaltrials.gov) - Apr 21, 2013
P4, N=500, Active, not recruiting, Sponsor: EndoGastric Solutions
N=50 --> 1 Recruiting --> Active, not recruiting
- Trial completion: The Effect of Food Taste, Temperature, and Viscosity on Swallowing Efficiency (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=1, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=19, Completed, Sponsor: University of California, Davis
Recruiting --> Completed N=100 --> 19
- Trial completion: Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin (clinicaltrials.gov) - Apr 21, 2013
P=N/A, N=19, Completed, Sponsor: University of California, Davis
N=100 --> 19 Recruiting --> Completed
- IMF-001 / ImmunoFrontier
Enrollment change: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer (clinicaltrials.gov) - Apr 15, 2013
P1, N=25, Completed, Sponsor: ImmunoFrontier, Inc.
Recruiting --> Completed N=20 --> 25
- | IMF-001 / ImmunoFrontier
Trial completion: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer (clinicaltrials.gov) - Apr 15, 2013
P1, N=25, Completed, Sponsor: ImmunoFrontier, Inc.
N=20 --> 25 Active, not recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Combination therapy: Study of S-1 in Combination With Radiotherapy in Esophageal Cancer (clinicaltrials.gov) - Apr 11, 2013
P2, N=105, Recruiting, Sponsor: Fudan University
- ||| rilotumumab (AMG 102) / Amgen
Trial initiation date, Metastases: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer (clinicaltrials.gov) - Apr 11, 2013
P1/2, N=130, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Initiation date: Aug 2008 --> Feb 2009
- metformin / Generic mfg.
Trial initiation date: Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus (clinicaltrials.gov) - Apr 10, 2013
P2, N=86, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2008 --> Feb 2009 Initiation date: Jan 2012 --> Jun 2012
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
New P2 trial: Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer (clinicaltrials.gov) - Apr 10, 2013
P2, N=61, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- metformin / Generic mfg.
Enrollment closed: Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus (clinicaltrials.gov) - Apr 10, 2013
P2, N=86, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2012 --> Jun 2012 Recruiting --> Active, not recruiting
- Trial termination, FDG PET, Metastases: HICON: Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (clinicaltrials.gov) - Apr 9, 2013
P2, N=0, Terminated, Sponsor: National Center for Tumor Diseases, Heidelberg
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- Enrollment open, Surgery: Prehabilitation for Esophageal Resection Surgery (clinicaltrials.gov) - Apr 7, 2013
P=N/A, N=68, Recruiting, Sponsor: Franco Carli
Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- Biomarker, Trial completion, Metastases: Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 6, 2013
P=N/A, N=239, Completed, Sponsor: Samsung Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P3 trial, Metastases: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients (clinicaltrials.gov) - Apr 2, 2013
P3, N=446, Not yet recruiting, Sponsor: Sun Yat-sen University
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial completion, Metastases: BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy (clinicaltrials.gov) - Apr 2, 2013
P2, N=0, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Completed Active, not recruiting --> Completed
- || Enrollment closed: Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux (clinicaltrials.gov) - Mar 27, 2013
P=N/A, N=170, Active, not recruiting, Sponsor: Wake Forest Baptist Health
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma (clinicaltrials.gov) - Mar 27, 2013
P2, N=126, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Clinical: The Diagnostics of Extraesophageal Reflux With the Restech System (clinicaltrials.gov) - Mar 25, 2013
P=N/A, N=90, Recruiting, Sponsor: University Hospital Ostrava
- PPC-5650 / PainCeptor
New P1 trial: A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus (clinicaltrials.gov) - Mar 24, 2013
P1, N=25, Completed, Sponsor: Asbj
- cisplatin / Generic mfg., irinotecan / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Metastases: Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Mar 20, 2013
P1, N=27, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=36 --> 27
- carboplatin / Generic mfg., paclitaxel / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Combination therapy: Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Mar 19, 2013
P1, N=13, Completed, Sponsor: Duke University
N=36 --> 27 N=36 --> 13
- Trial termination: TEFGoreHelex: Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device (clinicaltrials.gov) - Mar 17, 2013
P4, N=4, Terminated, Sponsor: University of Sao Paulo
N=36 --> 13 Recruiting --> Terminated; The study was terminated because the rate of prothesis dislocation was too high.
- Enrollment change: TEFGoreHelex: Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device (clinicaltrials.gov) - Mar 17, 2013
P4, N=4, Terminated, Sponsor: University of Sao Paulo
Recruiting --> Terminated; The study was terminated because the rate of prothesis dislocation was too high. N=10 --> 4
- sirolimus / Generic mfg.
New P1 trial: Sirolimus for Eosinophil-Associated Gastrointestinal Disorders (clinicaltrials.gov) - Mar 17, 2013
P1, N=75, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery, Metastases: Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Mar 11, 2013
P2, N=33, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=10 --> 4 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin (clinicaltrials.gov) - Mar 7, 2013
P2, N=16, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting N=25 --> 16
- ||||| Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
New P2 trial, Metastases: Oral Rigosertib for Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 6, 2013
P2, N=80, Active, not recruiting, Sponsor: Onconova Therapeutics, Inc.
- lansoprazole / Generic mfg.
Enrollment change: The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors (clinicaltrials.gov) - Feb 25, 2013
P4, N=102, Terminated, Sponsor: Dallas VA Medical Center
N=25 --> 16 N=37 --> 102
- | Enrollment closed: Esophagectomy: Sweet Versus Ivor-Lewis (ESVIL) (ECTOP-2001) (clinicaltrials.gov) - Feb 25, 2013
P3, N=280, Active, not recruiting, Sponsor: Fudan University
N=37 --> 102 Recruiting --> Active, not recruiting
- |||| Photofrin (porfimer sodium) / Advanz Pharma
Trial completion: Endoscopic Therapy of Early Cancer in Barretts Esophagus (clinicaltrials.gov) - Feb 25, 2013
P2, N=88, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- armodafinil / Generic mfg.
Enrollment open, P2 data: A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Biomarker, Enrollment open: Permission to Collect Blood Over Time for Research (clinicaltrials.gov) - Feb 24, 2013
P=N/A, N=345, Recruiting, Sponsor: Stanford University
Not yet recruiting --> Recruiting Withdrawn --> Recruiting
- Trial initiation date: Stroke Swallowing Screening Tool Validation (clinicaltrials.gov) - Feb 21, 2013
P=N/A, N=305, Recruiting, Sponsor: Department of Veterans Affairs
Withdrawn --> Recruiting Initiation date: Apr 2012 --> Oct 2012
- New P2 trial: Safety of Gastric Volume Emptying After the Intake of Maltodextrin and Glutamine (clinicaltrials.gov) - Feb 21, 2013
P2, N=11, Completed, Sponsor: Federal University of Mato Grosso do Sul
- |||| cabazitaxel / Generic mfg.
Enrollment open, Metastases: Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Feb 21, 2013
P2, N=86, Recruiting, Sponsor: Weill Medical College of Cornell University
Initiation date: Apr 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- New P2 trial, Metastases: ATTACK-OG: NY-ESO-1 T Cells in OG Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=28, Not yet recruiting, Sponsor: Fiona Thistlethwaite
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma (clinicaltrials.gov) - Feb 18, 2013
P2, N=50, Completed, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Photofrin (porfimer sodium) / Advanz Pharma
Trial initiation date: Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light (clinicaltrials.gov) - Feb 17, 2013
P2, N=0, Withdrawn, Sponsor: Pinnacle Biologics Inc.
Active, not recruiting --> Completed Initiation date: Jul 2012 --> May 2013
- esomeprazole / Generic mfg.
Enrollment open: BRAVO Study for Functional Dyspepsia (clinicaltrials.gov) - Feb 16, 2013
P4, N=130, Recruiting, Sponsor: Chinese University of Hong Kong
Initiation date: Jul 2012 --> May 2013 Not yet recruiting --> Recruiting
- Enrollment change: Efficacy & Safety of Submucosal Endoscopic Myotomy With Mucosal Flap (SEMF) in the Treatment of Patients With Achalasia (clinicaltrials.gov) - Feb 14, 2013
P=N/A, N=100, Recruiting, Sponsor: Winthrop University Hospital
Not yet recruiting --> Recruiting N=10 --> 100
- ||| Enrollment change: Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients (clinicaltrials.gov) - Feb 13, 2013
P2a, N=244, Completed, Sponsor: AstraZeneca
N=10 --> 100 N=306 --> 244
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Feb 12, 2013
P2, N=39, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=306 --> 244 Active, not recruiting --> Completed
- Enrollment change: The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=75, Completed, Sponsor: Bayside Health
Active, not recruiting --> Completed N=54 --> 75
- Trial completion: The Prevalence of Gastro-oesophageal Reflux in Chronic Lung Disease (clinicaltrials.gov) - Feb 11, 2013
P1/2, N=75, Completed, Sponsor: Bayside Health
N=54 --> 75 Recruiting --> Completed